CD8A and lung carcinoma: Compared with chemo or targeting therapy alone, add-on with Aidi injection showed consistent effects on three-year survival rate (2 RCTs), progression free survival (2 RCTs), KPS scores (12 RCTs), and immune function assessed by CD4 and CD4/CD8 (10 RCTs) in lung cancer patients (Figure 4).